Combined Oxidative Phosphorylation Deficiency 51 (COXPD51) Cell Models for Research

Combined Oxidative Phosphorylation Deficiency 51 (COXPD51) is an ultra-rare autosomal recessive mitochondrial disorder caused by mutations in the MRPS23 gene. Due to its rarity, exact prevalence is unknown; fewer than 10 cases have been reported in the literature. Onset typically occurs in infancy or early childhood, presenting with severe neurological symptoms, including hypotonia, developmental delay, seizures, and lactic acidosis. The condition is often fatal in early life. According to the WHO, mitochondrial disorders collectively affect approximately 1 in 5,000 individuals, but COXPD51 represents a very small fraction. The NCI does not track this disease as it is not a cancer. The clinical impact is profound, with most patients experiencing progressive neurodegeneration and multi-organ failure. Research significance lies in understanding mitochondrial translation and oxidative phosphorylation, which are fundamental to cellular energy metabolism.

COXPD51 serves as an ideal model for studying mitochondrial ribosome function and the assembly of oxidative phosphorylation complexes. The disease is caused by mutations in MRPS23, a component of the small mitochondrial ribosomal subunit. Researchers can use patient-derived fibroblasts or induced pluripotent stem cells (iPSCs) to model the disease in vitro. Public datasets, such as those in GEO, provide transcriptomic and proteomic profiles of patient cells. Open questions include the precise molecular mechanisms linking MRPS23 dysfunction to complex I and IV deficiencies, and potential therapeutic targets. The rarity of the disease makes it a niche but valuable area for mechanistic studies.

• • COXPD51 is not a cancer, but it involves defects in oxidative phosphorylation. The major pathways affected include:
• • Mitochondrial translation: MRPS23 is part of the small subunit of the mitochondrial ribosome, essential for translating 13 mitochondrial-encoded proteins.
• • Oxidative phosphorylation: Defects in mitochondrial translation lead to impaired assembly of complexes I, III, IV, and V, causing reduced ATP production and increased reactive oxygen species (ROS).
• • Cellular stress response: Mitochondrial dysfunction triggers the integrated stress response (ISR), activating ATF4 and other stress-responsive genes.
• • Apoptosis: Severe ATP depletion and ROS accumulation can lead to cell death, particularly in high-energy-demand tissues like neurons and muscle.

Data from ClinVar and literature reports.

• • Mitochondrial dysfunction in COXPD51 affects several signaling networks:
• • AMPK pathway: Activated in response to low ATP/AMP ratio, promoting catabolic processes.
• • mTOR pathway: Inhibited by energy stress, reducing protein synthesis and cell growth.
• • Integrated stress response (ISR): eIF2α phosphorylation leads to ATF4 translation, upregulating amino acid metabolism and antioxidant genes.
• • Calcium signaling: Mitochondrial calcium uptake is impaired, affecting cytosolic calcium dynamics and downstream pathways.
• • ROS signaling: Increased ROS can activate NF-κB and MAPK pathways, contributing to inflammation and apoptosis.

Organoids, such as cerebral organoids derived from patient iPSCs, can recapitulate brain development and mitochondrial dysfunction, providing a more physiologically relevant model.

• • Animal models for COXPD51 are limited due to the rarity of the disease. However, potential models include:
• • Knockout mouse models: Mrps23 knockout mice are likely embryonic lethal, but conditional knockouts in specific tissues (e.g., neurons) can be generated using Cre-lox systems.
• • Patient-derived xenografts (PDX): Not applicable for non-cancer diseases.
• • Genetically engineered mouse models (GEMM): Point mutations corresponding to human pathogenic variants can be introduced using CRISPR.
• • Zebrafish models: Morpholino or CRISPR-induced mrps23 knockdown can recapitulate mitochondrial defects.
• • Drosophila models: RNAi or mutation of mRpS23 can be used for genetic screens.

• • Gene-edited cell models are crucial for studying COXPD51. CRISPR-Cas9 technology allows the creation of isogenic cell lines with specific MRPS23 mutations. For example:
• • MRPS23 knockout cell lines: Complete loss of function to study null phenotypes.
• • MRPS23 point mutation knock-in lines: Introduction of patient-specific mutations (e.g., c.218G>A p.Arg73His) to study hypomorphic effects.
• • Reporter cell lines: Tagging MRPS23 with fluorescent proteins to track expression and localization.

These models are sequence-verified and can be generated in various backgrounds, including HEK293T, HeLa, and iPSCs. Commercially available, sequence-verified models accelerate research by providing consistent and reproducible tools. They are essential for drug screening, functional genomics, and mechanistic studies.

• • Knockout and knock-in cell lines are used to validate the function of MRPS23 and identify genetic modifiers. For example:
• • CRISPR knockout screens can identify genes that rescue or exacerbate mitochondrial dysfunction.
• • Isogenic pairs (wild-type vs. mutant) allow for differential gene expression analysis to uncover downstream pathways.
• • Overexpression or complementation studies can confirm the pathogenicity of specific mutations.

• • Isogenic cell lines are ideal for high-throughput drug screening. For COXPD51, potential therapeutic approaches include:
• • Screening for compounds that enhance mitochondrial biogenesis or function.
• • Testing drugs that modulate the integrated stress response.
• • Evaluating antioxidants to reduce ROS damage.
• • Resistance modeling: Cells with partial MRPS23 function may develop resistance to mitochondrial inhibitors, providing insights into drug resistance mechanisms.

CRISPR synthetic lethality screens can identify genes that are essential only in MRPS23-deficient cells. These genes could serve as therapeutic targets. Additionally, secretome analysis of mutant cells can identify secreted biomarkers for disease monitoring. For example, FGF21 and GDF15 are known biomarkers of mitochondrial dysfunction and can be measured in cell culture media.